文献速递产科母胎医学

ASPRE试验:阿司匹林预防下早产型子痫前期的危险因素

ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-09-06

本研究为ASPRE试验的二次分析,纳入1592例经FMF算法筛查的早产型子痫前期高危单胎孕妇,随机接受阿司匹林150mg/日或安慰剂。早产型子痫前期发生率为3.0%(n=48)。调整阿司匹林使用后,PlGF中位数倍数(MoM)和FMF估计风险组是独立预测因素;慢性高血压与阿司匹林存在显著交互作用(P=0.042),提示慢性高血压孕妇无治疗效应。

要点

  • FMF估计风险≥1/50者早产型子痫前期风险是1/51-1/100者的7倍(aOR 6.706)。
  • PlGF<0.712 MoM者早产型子痫前期风险显著升高(aOR 3.677)。
  • 慢性高血压与阿司匹林交互作用显著(P=0.042),该人群治疗效应缺失。

核心结论

  • 在FMF算法筛查的早产型子痫前期高危孕妇中,尽管使用阿司匹林预防,估计风险≥1/50、慢性高血压和PlGF<0.712 MoM仍与早产型子痫前期发生相关。

研究设计与样本

  • ASPRE试验的二次分析,纳入1592例经FMF算法(结合母体因素、平均动脉压、子宫动脉搏动指数、PAPP-A和PlGF)筛查为早产型子痫前期高危的单胎孕妇。
  • 高危孕妇随机接受阿司匹林150mg/日或安慰剂,从孕11-14周至孕36周。
  • 主要结局为孕37周前分娩的子痫前期(早产型子痫前期)。

主要发现

  • 1592例高危孕妇中早产型子痫前期发生率为3.0%(n=48)。
  • 阿司匹林使用与慢性高血压的交互作用显著(P=0.042),慢性高血压孕妇中未见治疗效应。
  • 调整阿司匹林使用、交互作用及其他协变量后,PlGF MoM(aOR 0.226,95%CI 0.070-0.723)和FMF估计风险组是早产型子痫前期的独立预测因素。
  • 与估计风险1/51-1/100相比,风险1/2-1/10者早产型子痫前期风险高7倍(aOR 6.706,95%CI 2.381-18.883),风险1/11-1/50者高3倍(aOR 2.769,95%CI 1.105-6.939)。
  • 在估计风险1/2-1/10者中PlGF MoM是独立预测因素(aOR 0.055,95%CI 0.005-0.668);在风险1/11-1/100者中阿司匹林使用是独立预测因素(aOR 0.276,95%CI 0.111-0.689)。

关键数值与推荐

  • 早产型子痫前期定义:孕37周前分娩的子痫前期。
  • FMF估计风险分组:1/2-1/10、1/11-1/50、1/51-1/100。
  • PlGF预测早产型子痫前期的截断值:0.712 MoM。

临床怎么用

  • 对FMF筛查估计风险≥1/50的早产型子痫前期高危孕妇,应加强监测并考虑额外干预。
  • 慢性高血压孕妇使用阿司匹林预防早产型子痫前期的效应可能有限,需个体化评估。
  • PlGF<0.712 MoM可作为阿司匹林预防下仍发生早产型子痫前期的预警指标。

局限性

  • 本研究为ASPRE试验的二次分析,结果需进一步外部验证。
  • 早产型子痫前期事件数较少(n=48),部分亚组分析效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the possible risk factors amongst maternal characteristics, medical and obstetric history, pre-eclampsia (PE)-specific biomarkers and estimated-risk group, according to The Fetal Medicine Foundation (FMF) algorithm, that are associated with the development of preterm PE with delivery at < 37 weeks' gestation despite aspirin prophylaxis. METHODS: This was a secondary analysis of data from the ASPRE trial. The study population consisted of women with singleton pregnancy who were deemed to be at high risk for preterm PE, based on the FMF algorithm that combines maternal factors, mean arterial pressure, uterine artery pulsatility index, serum pregnancy-associated plasma protein-A and placental growth factor (PlGF) at 11-13 weeks' gestation. High-risk women were randomized to receive aspirin (150 mg/day) vs placebo from 11-14 until 36 weeks' gestation. The primary outcome was PE with delivery at < 37 weeks' gestation (preterm PE). Multivariate logistic regression analysis was performed to identify independent predictors of preterm PE after adjusting for the use of aspirin and other covariates. RESULTS: Among 1592 high-risk women, the incidence of preterm PE was 3.0% (n = 48). The interaction between aspirin usage and history of chronic hypertension was significant in the prediction of preterm PE (P = 0.042), which indicated that there was no treatment effect in high-risk women who had chronic hypertension compared with those who did not. Adjusting for aspirin use, the interaction between aspirin and chronic hypertension and other covariates, independent predictors for the development of preterm PE were PlGF multiples of the median (MoM) (adjusted odds ratio (aOR), 0.226 (95% CI, 0.070-0.723)) and estimated-risk group based on the FMF algorithm. Compared to women with an estimated risk of 1 in 51 to 1 in 100, those with an estimated risk of 1 in 2 to 1 in 10 had a 7-fold higher risk of developing preterm PE (aOR, 6.706 (95% CI, 2.381-18.883)), and those with an estimated risk of 1 in 11 to 1 in 50 had a 3-fold higher risk of preterm PE (aOR, 2.769 (95% CI, 1.105-6.939)). PlGF MoM was an independent predictor for preterm PE among women with an estimated risk of 1 in 2 to 1 in 10 (aOR, 0.055 (95% CI, 0.005-0.668)). Among women with an estimated risk of 1 in 11 to 1 in 100, the use of aspirin was an independent predictor of preterm PE (aOR, 0.276 (95% CI, 0.111-0.689)). The cut-off for PlGF with the best performance for the prediction of preterm PE was 0.712 MoM, with an aOR of 3.677 (95% CI, 1.526-8.862). CONCLUSION: In pregnancies at high risk of preterm PE identified by screening at 11-13 weeks' gestation using the FMF algorithm, a very high-risk result (estimated risk ≥ 1 in 50), compared to an estimated risk of 1 in 51 to 1 in 100, chronic hypertension, compared to no chronic hypertension, and low PlGF concentration (< 0.712 MoM), compared to PlGF ≥ 0.712 MoM, were associated with the development of preterm PE despite aspirin prophylaxis. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Shen L, Martinez-Portilla RJ, Rolnik DL, et al. ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis. Ultrasound Obstet Gynecol. 2021. PMID: 33998099. doi:10.1002/uog.23668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。